Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
• 5 min read
• Published on 8 November 2025
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
The Great Weight-Loss Windfall: A Sober Look at Pharma's Next Big Thing
Let’s be honest, when a government body, particularly an American one, makes a swift and decisive move, it’s usually a sign to pay attention. For decades, Medicare, the colossal US state health insurer, stubbornly refused to pay for weight-loss drugs. They were seen as a vanity project, a lifestyle choice. Now, in a complete reversal, they’ve opened the public purse. To me, this isn’t just a healthcare story, it’s a flashing neon sign for any investor with a pulse.
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
When the starting gun fires, it pays to back the favourites. In this race, the thoroughbreds are undoubtedly Eli Lilly and Novo Nordisk. These two giants have effectively cornered the market with their GLP-1 drugs, you know them as Ozempic, Wegovy, and Mounjaro. They’ve already built the factories, navigated the regulatory mazes, and established brands that are now household names. With Medicare now footing the bill for millions of potential new customers, the primary barrier to entry, a price tag of over a thousand pounds a month, has simply vanished. This isn't about creating a market, it's about unlocking a colossal one that was already there, just waiting. The demand is practically insatiable, and these two firms are holding the only taps.
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
Of course, no duopoly lasts forever. The current crop of wonder drugs has an Achilles' heel, they require weekly injections. It’s a bit of a faff, isn't it? This creates a tantalising opportunity for smaller, nimbler biotech firms. The holy grail is a simple pill that does the same job. Companies are pouring fortunes into clinical trials for oral alternatives, and if one of them cracks the code, they could disrupt the entire landscape. Investing in these innovators is certainly a riskier proposition. It’s a bet on the science paying off. But the potential reward, should they succeed, is astronomical. It’s the classic David versus Goliath story, played out in laboratories and boardrooms.
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
I find that investors often get mesmerised by the shiny, headline-grabbing drug makers. They forget that for every blockbuster drug, there’s a vast, unseen network required to get it from the factory to the patient. Think of firms like McKesson or Cardinal Health as the plumbers of the pharmaceutical world. They handle the logistics, and their fees are tied to volume and value. More expensive drugs moving in greater numbers means more profit for them. Then you have the high street chemists like CVS and Walgreens. They are the final, crucial link in the chain. This surge in prescriptions is a straightforward volume game for them, and it’s a game they are perfectly positioned to win without taking on any of the research and development risk.
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
Now, before you rush off and remortgage the house, a dose of reality is in order. Government intervention is a double-edged sword. Yes, Medicare is creating the market, but it is also negotiating prices quite aggressively. This could put a cap on the frankly eye-watering profit margins these companies have enjoyed. To me, the whole situation is a fascinating case study in the Obesity Drug Pricing | Pharma Investment Theme, where government policy directly creates and shapes a market. There are also manufacturing hurdles to consider, as shortages have already shown. And let’s not forget the patent cliff, that inevitable moment when generic competition arrives. This isn't a risk-free bet, it's a calculated one based on a monumental policy shift.
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
View the full Basket:Obesity Drug Pricing | Pharma Investment Theme
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article